Clinical and genetic analysis of pediatric catecholaminergic polymorphic ventricular tachycardia: focus on sinus bradycardia and neurodevelopmental disorders - Takeaways - MDSpire

Clinical and genetic analysis of pediatric catecholaminergic polymorphic ventricular tachycardia: focus on sinus bradycardia and neurodevelopmental disorders

  • By

  • Lianfu Ji

  • Shiwei Yang

  • Qian Wang

  • Fan Yang

  • Jie Yin

  • Mei Chen

  • Jinlong Chen

  • May 28, 2026

  • 0 min

Share

  • 1

    Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a hereditary arrhythmia with a high mortality risk and heterogeneous clinical presentation.

  • 2

    The study analyzed seven pediatric CPVT patients, revealing a median age of onset of 7.7 years and significant diagnostic delays.

  • 3

    Notable clinical features included sinus bradycardia in one patient and neurodevelopmental disorders in two patients, complicating management.

  • 4

    Genetic testing identified four patients with RYR2 variants, including two novel mutations, and three with variants in other genes.

  • 5

    Enhanced awareness of CPVT's complex presentations is crucial for optimizing outcomes, particularly regarding sinus bradycardia and neurodevelopmental disorders.

Original Source(s)

Clinical and genetic analysis of pediatric catecholaminergic polymorphic ventricular tachycardia: focus on sinus bradycardia and neurodevelopmental disorders

  • by Lianfu Ji, Shiwei Yang, Qian Wang, Fan Yang, Jie Yin, Mei Chen, Jinlong Chen

  • May 28, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

School-Based Screening Detected Undiagnosed Hypertension

Novel program enabled large-scale blood pressure screening and identified elevated readings in community setting.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.